Harvoni

Harvoni is an oral tablet that combines ledipasvir 90 mg and sofosbuvir 400 mg in a fixed‑dose combination. The medication belongs to the direct‑acting antiviral class and is prescribed for chronic hepatitis C virus infection. It is available by prescription in the European market and works by targeting two essential viral proteins, disrupting replication and assembly of the hepatitis C virus. It is taken with food and is part of regimens for HCV genotypes.

Harvoni is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, either as a standalone regimen or in combination with other antiviral agents when appropriate.

- Patients infected with HCV genotype 1 (including subtypes 1a and 1b), regardless of prior treatment status. - Individuals diagnosed with HCV genotype 4 infection, which is prevalent in certain regions of the Middle East and Africa. - Adults with chronic HCV genotype 5 infection, a less common genotype found primarily in South Africa. - Patients harboring HCV genotype 6 infection, which is more frequently observed in Southeast Asia. - Those with compensated cirrhosis who meet specific clinical criteria, allowing use of Harvoni without ribavirin.

Harvoni may cause a range of side effects, most of which are mild to moderate and resolve without intervention. The frequency and severity of these events vary among individuals.

Common: - Fatigue or a feeling of tiredness that may affect daily activities. - Headache, ranging from mild to moderate intensity. - Nausea or an upset stomach, sometimes accompanied by loss of appetite. - Diarrhea, which is usually mild and transient.

Serious: - Severe allergic reaction, including rash, itching, swelling of the face or throat, or difficulty breathing, which requires immediate medical attention. - Significant elevations in liver enzymes (ALT/AST) indicating possible liver injury, especially in patients with pre‑existing liver disease.

When prescribing Harvoni, clinicians should consider several precautions to ensure safe and effective use.

- Assess liver function before initiating therapy, especially in patients with cirrhosis. - Monitor for potential drug–drug interactions, as Harvoni is metabolized via hepatic pathways. - Use caution in patients with renal impairment; dose adjustment may be required for co‑administered agents. - Counsel women of childbearing potential about contraception, as pregnancy category B indicates limited data. - Discontinue or adjust therapy if severe adverse reactions such as allergic reactions or significant liver enzyme elevations occur.

Harvoni can interact with other medications; understanding these interactions helps prevent reduced efficacy or increased toxicity.

Avoid: - Strong inducers of CYP3A4 such as rifampin, carbamazepine, and phenytoin, which may lower Harvoni plasma levels. - Antiretroviral agents like efavirenz that significantly reduce drug exposure. - Concomitant use of certain HIV protease inhibitors (e.g., ritonavir) may increase sofosbuvir exposure and requires monitoring.

Use with caution: - Amiodarone, due to the risk of serious bradycardia when combined with Harvoni. - Certain statins (e.g., simvastatin, lovastatin) that may increase statin concentrations. - Proton pump inhibitors (e.g., omeprazole) that can reduce ledipasvir absorption. - Herbal supplements such as St. John’s wort, a CYP3A4 inducer, may reduce Harvoni effectiveness.